Pediatric Oncology Labeling Should Reflect Exploratory Approach – Pazdur
Executive Summary
Oncologic drug pediatric labeling should reflect the exploratory nature of the field, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said during an advisory committee meeting March 4
You may also be interested in...
Barr Expects Metformin Launch By Early February; Pediatric Bill Signed
Barr plans to launch its generic version of Bristol-Myers Squibb's Glucophage (metformin) by early February, CEO Bruce Downey said Jan. 10
Pediatric Access To Unapproved Drugs Is Next Topic For Oncology Subcmte
Pediatric use of unapproved cancer drugs will be the next topic on the table for FDA's Pediatric Subcommittee of the Oncologic Drugs Advisory Committee
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011